4507 Shionogi
- 6301.0
- -934.0-12.91%
Shionogi News
Shionogi: Eisai Research and Development Commemoration Day 2024
Shionogi: Eisai Research and Development Commemoration Day 2024
Shionogi: Independent Officer Notification Form
Shionogi: Position and policy on the reduction of investment units
Shionogi: The way of thinking and policies, etc. relating to the reduction of investment units
Correction Report (Mass Ownership Report/Change Report)
Shionogi: Notice of Convocation of the Annual General Meeting and Meeting Materials 2024
Shionogi: 2024 Annual General Shareholders' Meeting Convocation Notice and Shareholders' Meeting Materials
Shionogi: Shionogi & Co., Ltd. provides an update on SCORPIO-HR, a global phase 3 trial of encitrelvir targeting non-hospitalized participants with COVID-19
Shionogi: 2023 Financial Results
Shionogi: Results of the global phase 3 clinical trial (SCORPIO-HR) of the novel coronavirus infection (COVID-19) remedy encitrelbyl fumarate
Shionogi: 2023 financial results briefing materials
Shionogi: Financial results for the year ended March 31, 2024
Shionogi: Consolidated Financial Results (IFRS) for Fiscal Year 2023
Shionogi: Financial results for the fiscal year ending 2024/3 (supplementary materials)
Shionogi: Summary of financial results for the fiscal year ending 2024/3 [IFRS] (consolidated)
Shionogi: World exclusive license agreement for MZE001, a novel therapeutic candidate for the treatment of Pompe disease
Shionogi: Concluding a license agreement with Maze regarding the introduction of new drug candidates for Pompe disease
Change Report
Shionogi: Notice regarding revisions (dividend increases) to the dividend forecast for the fiscal year ending 2024/3
Analysis
Price Target
No Data
